3 edition of New fluoroquinolones in community-acquired pseumonia found in the catalog.
New fluoroquinolones in community-acquired pseumonia
by Canadian Coordinating Office for Health Technology Assessment in Ottawa
|Series||Technology report (Canadian Coordinating Office for Health Technology Assessment) -- issue 20|
|Contributions||Metge, Colleen J., Canadian Coordinating Office for Health Technology Assessment|
|The Physical Object|
|Pagination||x, 75 p.|
|Number of Pages||75|
Based on emerging new evidence, a multidisciplinary panel of experts put together by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) released updated recommendations for the management of adults with community-acquired pneumonia (CAP). Guidelines recommend macrolides and fluoroquinolones in patients hospitalized with community-acquired pneumonia (CAP), but their use has been associated with cardiac events. We quantified associations between macrolide and fluoroquinolone use and cardiac events in patients hospitalized with CAP in non-ICU by: 4.
Community-aquired pneumonia is associated with a high degree of morbidity and mortality, and the initial diagnosis and treatment decision, . Fluoroquinolones in the management of community-acquired pneumonia in primary care Article Literature Review in Expert Review of Anti-infective Therapy 8(11) .
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia For the first time in more than 15 years, the FDA has approved a systemic antibacterial drug with a novel mechanism of action to combat community-acquired bacterial pneumonia (CABP).Author: Rebecca Voelker. Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community-acquired pneumonia (CAP). Methods: Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicrobial therapy in managing CAP, with a focus on current North American by:
Blaze the Ice Dragon
PERSONALITY COHERENCE AND INCOHERENCE
Single property schemes.
Family in post-industrial America
Everything is illuminated
20 greatest movie directors of all time.
Hearings on National Defense Authorization Act for fiscal year 2005--H.R. 4200 and oversight of previously authorized programs before the Committee on Armed Services, House of Representatives, One Hundred Eighth Congress, second session, Strategic Forces Subcommittee hearings on title I--procurement, title II--research, development, test, and evaluation, title X--general provisions, title XXXI--Department of Energy national security programs, title XXXII--Defense Nuclear Facilities Safety Board, hearings held February 25, March 18, 25, 2004.
Fluoroquinolones in the management of community-acquired pneumonia. Albertson TE(1), Dean NC, El Solh AA, Gotfried MH, Kaplan C, Niederman MS. Author information: (1)Department of Internal Medicine, UC Davis School of Medicine, Davis, CA, by: To the Editor: Wunderink and Waterer (Feb.
6 issue)1 summarize antimicrobial agents, including fluoroquinolones, that are safe and effective for the treatment of community-acquired pneumonia. Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community‐acquired pneumonia (CAP).
Methods: Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicrobial therapy in managing CAP, with a focus on current North American by: The new fluoroquinolones in community-acquired pneumonia: Clinical and economic perspectives.
Cite as: Metge CJ, Vercaigne New fluoroquinolones in community-acquired pseumonia book, Carrie A, Sarveiya V, Zhanel GG. The new fluoroquinolones in community-acquired pneumonia: clinical and economic perspectives.
Fluoroquinolone use has dramatically increased since the introduction of the first respiratory fluoroquinolone in the late s. Over a relatively brief period of time, the respiratory fluoroquinolones have supplanted other first-line options as the predominant community-acquired pneumonia (CAP) therapy in by: Community-acquired pneumonia (CAP) is a common and important disease that occurs in all age groups worldwide.
Streptococcus pneumoniae is the most common cause of CAP and is the pathogen associated with the greatest morbidity and mortality .High-level penicillin-resistant and drug-resistant S. pneumoniae infections are now a global problem; thus, the number of therapeutic options Cited by: CiteULike.
About this book. Community-Acquired Pneumonia (CAP)refers to pneumonia acquired outside of hospitals or extended-care facilities, and is distinct from Nosocomial or hospital-acquired pneumonia, which is a separate disease entity.
It is one of the most common respiratory infections and presents one of the major health problems today, with an incidence that ranges from eight to fifty. Fluoroquinolone Treatment of Community-Acquired Pneumonia: A Meta-Analysis Article in Annals of Pharmacotherapy 36(12) January with 67 Reads How we measure 'reads'.
The new respiratory fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and on the horizon, garenoxacin) offer many improved qualities over older agents such as ciprofloxacin. These include retaining excellent activity against Gram-negative bacilli, with improved Gram-positive Cited by: Publisher Summary.
This chapter provides an overview of the quinolone antibacterials. Since the mids, the fluoroquinolones have become a major group of synthetic antibiotics with activities ranging from the Enterobacteriaceae and opportunists such as Pseudomonas aeruginosa to the Gram-positive pathogens including streptococci and staphylococci.
In some areas such as pyelonephritis. Based on recent guidelines for the management of community-acquired pneumonia, this study was designed to evaluate the effectiveness of a new fluoroquinolone compared with standard antimicrobial regimens, in conditions relating as closely as possible to the real world setting.
In this study, patients were randomised to either oral moxifloxacin ( mg o.d.) or to standard oral therapy Cited by: The new fluoroquinolones are extensively distributed into many tissues and fluids. The distribution of four of the new fluoroquinolones, grepafloxacin, levofloxacin, sparfloxacin and trovafloxacin, into selected tissues and fluids is presented in Table 6 (,–).
Little data exist on the tissue and fluid distribution of the. Community-acquired pneumonia (CAP) is a leading cause of hospitalization and death worldwide. Most guidelines recommend that antibiotic treatment be based on the severity of disease at Cited by: Clinical presentation.
Community-acquired pneumonia is responsible for great mortality and morbidity and high costs. Community-acquired pneumonia was featured in Seminars in The Lancet in 1 and 2 In this updated Seminar, we address important topics related to community-acquired pneumonia in immunocompetent adults.
Suspected community-acquired pneumonia is defined by acute Cited by: Background: The choice of empirical antibiotic treatment for patients with community-acquired pneumonia (CAP) who are admitted to non-intensive care unit (ICU) hospital wards is complicated by the limited availability of evidence.
We systematically reviewed the efficacy and safety of strategies of empirical treatment with respiratory fluoroquinolone monotherapy and β-lactam with or without Cited by: 1.
Newer fluoroquinolones may play an important role in the management of community acquired pneumonia. They retain activity similar to older fluoroquinolones against Gram-negative bacteria and are significantly more active against Gram-positive bacteria, especially by: 7. JNJ-Q2 is a novel fluoroquinolone antibiotic with broad-spectrum bactericidal activity, including excellent activity against MRSA and DRSP.5 Unlike other fluoroquinolones, JNJ-Q2 has an improved balance in the potencies of inhibition of DNA gyrase and DNA topoisomerase IV, which is thought to decrease the development of drug resistance,15,21 Multiple in vivo and in vitro Cited by: 6.
Community-acquired pneumonia (CAP) is a leading cause of death due to infection in the United States and a primary indication for antimicrobial drug use in inpatient and outpatient settings.
The fluoroquinolone class of antimicrobial agents has become increasingly popular for the management of CAP because of coverage of common CAP pathogens Cited by: INTRODUCTION. Community-acquired pneumonia (CAP) is the leading cause of death worldwide, with a significant impact on morbidity rates.
1 Despite the vast diversity of respiratory microbiota, the widespread dissemination of potentially pathogenic agents, the phenomenon of globalization, and the occurrence of viral epidemics, Streptococcus pneumoniae remains the most. In India, tuberculosis accounts for 7% cases of community-acquired pneumonia.
The empirical antibiotic recommendations made by these guidelines advocate the use of a newer fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin) to treat almost all categories of patients with community-acquired by:.
Summary. Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the management of community-acquired pneumonia (CAP). Methods: Data were collected from recent clinical trials on fluoroquinolone therapy in patients with CAP and from updated recommendations of antimicrobial therapy in managing CAP, with a focus on current North American guidelines.
The respiratory fluoroquinolones are also generally well tolerated, and are first-line options for outpatient treatment of CAP in patients with comorbidities or previous antibiotic use.
Keywords:: antimicrobial resistance, antimicrobials, community-acquired pneumonia, fluoroquinolones, pharmacodynamics, pharmacokinetics, primary careCited by: A literature search was conducted using PubMed and MEDLINE databases from 1 January to 8 April using combined search terms of community-acquired pneumonia, fluoroquinolones, levofloxacin.